Annual Retained Earnings
-$7.29 B
-$278.16 M-3.97%
December 31, 2024
Summary
- As of February 20, 2025, ALNY annual retained earnings is -$7.29 billion, with the most recent change of -$278.16 million (-3.97%) on December 31, 2024.
- During the last 3 years, ALNY annual retained earnings has fallen by -$1.85 billion (-34.01%).
- ALNY annual retained earnings is now -162391.59% below its all-time high of -$4.49 million, reached on December 31, 2002.
Performance
ALNY Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Retained Earnings
-$7.29 B
-$83.76 M-1.16%
December 31, 2024
Summary
- As of February 20, 2025, ALNY quarterly retained earnings is -$7.29 billion, with the most recent change of -$83.76 million (-1.16%) on December 31, 2024.
- Over the past year, ALNY quarterly retained earnings has dropped by -$278.16 million (-3.97%).
- ALNY quarterly retained earnings is now -24589.17% below its all-time high of -$29.52 million, reached on December 31, 2003.
Performance
ALNY Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Retained Earnings Formula
Retained Earnings = Retained Earnings (start of the period) + Net Income − Dividends Paid
ALNY Retained Earnings Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -4.0% | -4.0% |
| 3 y3 years | -34.0% | -4.0% |
| 5 y5 years | -95.5% | -4.0% |
ALNY Retained Earnings Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -34.0% | at low | -34.0% | at low |
| 5 y | 5-year | -95.5% | at low | -95.5% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | at low |
Alnylam Pharmaceuticals Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | -$7.29 B(+4.0%) | -$7.29 B(+1.2%) |
| Sep 2024 | - | -$7.20 B(+1.6%) |
| Jun 2024 | - | -$7.09 B(+0.2%) |
| Mar 2024 | - | -$7.08 B(+0.9%) |
| Dec 2023 | -$7.01 B(+6.7%) | -$7.01 B(+2.0%) |
| Sep 2023 | - | -$6.87 B(-2.1%) |
| Jun 2023 | - | -$7.02 B(+4.1%) |
| Mar 2023 | - | -$6.74 B(+2.7%) |
| Dec 2022 | -$6.57 B(+20.8%) | -$6.57 B(+3.3%) |
| Sep 2022 | - | -$6.36 B(+6.8%) |
| Jun 2022 | - | -$5.96 B(+4.9%) |
| Mar 2022 | - | -$5.68 B(+4.4%) |
| Dec 2021 | -$5.44 B(+18.6%) | -$5.44 B(+5.0%) |
| Sep 2021 | - | -$5.18 B(+4.1%) |
| Jun 2021 | - | -$4.98 B(+4.0%) |
| Mar 2021 | - | -$4.79 B(+4.4%) |
| Dec 2020 | -$4.59 B(+23.0%) | -$4.59 B(+5.6%) |
| Sep 2020 | - | -$4.34 B(+6.2%) |
| Jun 2020 | - | -$4.09 B(+4.6%) |
| Mar 2020 | - | -$3.91 B(+4.9%) |
| Dec 2019 | -$3.73 B(+31.2%) | -$3.73 B(+8.0%) |
| Sep 2019 | - | -$3.45 B(+6.4%) |
| Jun 2019 | - | -$3.24 B(+7.3%) |
| Mar 2019 | - | -$3.02 B(+6.4%) |
| Dec 2018 | -$2.84 B(+32.3%) | -$2.84 B(+8.0%) |
| Sep 2018 | - | -$2.63 B(+10.3%) |
| Jun 2018 | - | -$2.38 B(+7.4%) |
| Mar 2018 | - | -$2.22 B(+3.4%) |
| Dec 2017 | -$2.15 B(+29.6%) | -$2.15 B(+7.1%) |
| Sep 2017 | - | -$2.01 B(+6.5%) |
| Jun 2017 | - | -$1.88 B(+6.7%) |
| Mar 2017 | - | -$1.76 B(+6.5%) |
| Dec 2016 | -$1.66 B(+32.9%) | -$1.66 B(+7.3%) |
| Sep 2016 | - | -$1.54 B(+7.2%) |
| Jun 2016 | - | -$1.44 B(+6.7%) |
| Mar 2016 | - | -$1.35 B(+8.3%) |
| Dec 2015 | -$1.25 B(+30.3%) | -$1.25 B(+7.8%) |
| Sep 2015 | - | -$1.16 B(+7.1%) |
| Jun 2015 | - | -$1.08 B(+7.1%) |
| Mar 2015 | - | -$1.01 B(+5.3%) |
| Dec 2014 | -$956.63 M | -$956.63 M(+2.3%) |
| Sep 2014 | - | -$935.24 M(+4.9%) |
| Jun 2014 | - | -$891.25 M(+5.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | -$847.18 M(+42.1%) |
| Dec 2013 | -$596.24 M(+17.6%) | -$596.24 M(+5.7%) |
| Sep 2013 | - | -$563.88 M(+5.6%) |
| Jun 2013 | - | -$534.19 M(+3.5%) |
| Mar 2013 | - | -$516.02 M(+1.8%) |
| Dec 2012 | -$507.01 M(+26.4%) | -$507.01 M(+14.0%) |
| Sep 2012 | - | -$444.82 M(+4.6%) |
| Jun 2012 | - | -$425.32 M(+3.1%) |
| Mar 2012 | - | -$412.36 M(+2.8%) |
| Dec 2011 | -$401.00 M(+16.8%) | -$401.00 M(+3.7%) |
| Sep 2011 | - | -$386.69 M(+3.5%) |
| Jun 2011 | - | -$373.46 M(+3.8%) |
| Mar 2011 | - | -$359.63 M(+4.7%) |
| Dec 2010 | -$343.35 M(+14.5%) | -$343.35 M(+2.1%) |
| Sep 2010 | - | -$336.42 M(+2.9%) |
| Jun 2010 | - | -$326.79 M(+4.7%) |
| Mar 2010 | - | -$312.15 M(+4.1%) |
| Dec 2009 | -$299.83 M(+18.9%) | -$299.83 M(+2.7%) |
| Sep 2009 | - | -$292.04 M(+3.3%) |
| Jun 2009 | - | -$282.83 M(+8.7%) |
| Mar 2009 | - | -$260.13 M(+3.1%) |
| Dec 2008 | -$252.24 M(+11.6%) | -$252.24 M(+3.9%) |
| Sep 2008 | - | -$242.85 M(+1.2%) |
| Jun 2008 | - | -$239.99 M(+5.6%) |
| Mar 2008 | - | -$227.23 M(+0.5%) |
| Dec 2007 | -$225.99 M(+60.8%) | -$225.99 M(-0.7%) |
| Sep 2007 | - | -$227.66 M(+30.2%) |
| Jun 2007 | - | -$174.86 M(+7.8%) |
| Mar 2007 | - | -$162.17 M(+15.4%) |
| Dec 2006 | -$140.53 M(+32.7%) | -$140.53 M(+6.4%) |
| Sep 2006 | - | -$132.09 M(+5.9%) |
| Jun 2006 | - | -$124.69 M(+8.6%) |
| Mar 2006 | - | -$114.78 M(+8.4%) |
| Dec 2005 | -$105.92 M(+68.1%) | -$105.92 M(+15.8%) |
| Sep 2005 | - | -$91.43 M(+13.2%) |
| Jun 2005 | - | -$80.75 M(+16.0%) |
| Mar 2005 | - | -$69.60 M(+10.5%) |
| Dec 2004 | -$63.01 M(+113.4%) | -$63.01 M(+9.9%) |
| Sep 2004 | - | -$57.30 M(+12.6%) |
| Jun 2004 | - | -$50.89 M(+15.8%) |
| Mar 2004 | - | -$43.93 M(+48.8%) |
| Dec 2003 | -$29.52 M(+558.1%) | -$29.52 M |
| Dec 2002 | -$4.49 M | - |
FAQ
- What is Alnylam Pharmaceuticals annual retained earnings?
- What is the all time high annual retained earnings for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual retained earnings year-on-year change?
- What is Alnylam Pharmaceuticals quarterly retained earnings?
- What is the all time high quarterly retained earnings for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly retained earnings year-on-year change?
What is Alnylam Pharmaceuticals annual retained earnings?
The current annual retained earnings of ALNY is -$7.29 B
What is the all time high annual retained earnings for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual retained earnings is -$4.49 M
What is Alnylam Pharmaceuticals annual retained earnings year-on-year change?
Over the past year, ALNY annual retained earnings has changed by -$278.16 M (-3.97%)
What is Alnylam Pharmaceuticals quarterly retained earnings?
The current quarterly retained earnings of ALNY is -$7.29 B
What is the all time high quarterly retained earnings for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly retained earnings is -$29.52 M
What is Alnylam Pharmaceuticals quarterly retained earnings year-on-year change?
Over the past year, ALNY quarterly retained earnings has changed by -$278.16 M (-3.97%)